Wire · founder news, decoded · opportunities
FDA plans to release more CRLs as controversial policy resumes
The FDA is resuming its policy of publicly releasing drug rejection letters (CRLs) after a three-month pause, with redaction procedures now formalized to address industry concerns over competitive harm and disclosure of trade secrets.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
Your competitor's rejection letters are now public documents. Every failed trial, every manufacturing flag, every clinical shortcut that cost them years—you'll see it weeks after they do, and you can use it to accelerate your own path.
Read the full story at fiercebiotech.com →
Topics: Digital Health · fda-crl-release · drug-approval-transparency · regulatory-disclosure · competitive-intelligence